Yuhan Corporation Q1 2026: Revenue up 7.2%, Operating Profit up 37.3% – Lazertinib Global Approvals and Enhanced Shareholder Returns via Treasury Share Cancellation | Yuhan(000100)

Consolidated revenue: KRW 526.8bn, operating profit: KRW 8.8bn, net profit: KRW 23.4bn (YoY +7.2%, +37.3%, +133.5% respectively)
Innovative drug Lazertinib obtained marketing approvals in major global markets (US, EU, Japan, Korea, China) for combination therapy; included as preferred regimen in NCCN guidelines
Treasury share cancellation: completed cancellation of 320,836 common shares in Jan 2026 (following 240,627 shares in May 2025)
Dividend policy: targeting total shareholder return rate ≥30% of net income (separate) as per Value-up Program; actual 43% in 2025
R&D expenses: KRW 54.7bn (10.4% of revenue); continuous expansion of pipeline
Key pipeline: YH14618 (US Phase 3), YH35324 (Lesigercept, global Phase 2) progressing as planned

ADVERTISEMENT (250px+)